Nice progress. Going about things the right way and hitting...

Nice progress. Going about things the right way and hitting targets as per the info in the last quarterly.

The last points to be completed by March 2013 were:

5. Manufacture initial market testing quantities.
6. Finalise initial market entry plan and place product with selected end users.
7. Commence development on new products, some in conjunction with partners.

The market depth is looking healthier now, which sadly imo previously put new buyers off when it was heavily weighted with sellers.

I am still keen to hear more about the additional areas of focus for their IP mentioned in the half yearly report:

- hand held electronic drug testing
- genomic testing (very interesting imo)
- disease diagnostics (incl asthma)
- other therapeutic acquisitions/transactions

Oral fluid testing for drugs imo is great and may provide excellent cashflow, but real value (i'm talking many multiples of current price) lies in the company's ability to make real progress in any or all of the above additional areas.